Guangdong Hybribio Biotech CO.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangdong Kaipu Biotechnology Co., Ltd. is a domestic developer and supplier of nucleic acid molecular diagnostic products, focusing on the research and development, production, sales, and provision of related services for nucleic acid diagnostic products such as molecular diagnostic reagents and molecular diagnostic supporting instruments. In 2016, Kepu's "Human Papillomavirus Genotyping Detection Kit and Its Gene Chip Preparation Method (ZL200710030723.6)" won the 18th China Invention Patent Gold Award, representing the advanced level of independent innovation in HPV testing in China. On April 12, 2017, Kepu Biotechnology (300639) made its initial public offering of shares and was listed on the ChiNext board. With independent innovation, Kepu was rated as a high-tech enterprise in 2008 and an innovative enterprise in Guangdong Province in 2012. In the same year, it was approved by the Guangdong Provincial Department of Science and Technology, the National Development and Reform Commission, and the Economic and Information Technology Commission to build the "Guangdong Provincial Molecular Diagnosis Engineering Technology Research and Development Center for Human Papillomavirus (HPV) Related Diseases", becoming one of the few enterprises in the field of molecular diagnosis in China that has the ability to build provincial-level research and development centers. In 2013, Kepu was approved by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee to establish a postdoctoral research workstation. In September 2015, the national strategic emerging industry development special project - Guangdong Kaipu Biochip R&D Industrial Base - was officially launched in Guangzhou Zhongxin Knowledge City. The organic combination of industry, academia, and research formed a dual chain development model of biotechnology chain and industry chain with Kaipu characteristics. In 2017, Kepu was awarded the titles of "National Intellectual Property Advantage Enterprise" and "National Gene Testing Technology Application Demonstration Center". In 2018, Kepu was approved by the Guangdong Provincial Department of Human Resources and Social Security to establish the Guangdong Provincial Doctoral Workstation. Kepu has always focused on independent research and development of molecular diagnostic technology, actively expanding the application fields of nucleic acid molecular diagnostic technology, and continuously promoting the transformation and upgrading of nucleic acid molecular diagnostic application technology. Among them, the diversion hybridization technology platform with independent intellectual property rights combines multiple technological advantages such as PCR amplification technology, molecular diversion hybridization technology, and biochip technology, greatly improving clinical diagnostic efficiency and accuracy. Multiple laboratories around the world have participated in the WHOHPV network monitoring and evaluation organized by the World Health Organization (WHO) using Kepu products for six consecutive times, and the results fully meet the clinical application level and laboratory capacity requirements. The pursuit of the country is the pursuit of Kep. Kepu has long organized and participated in the two cancer screening projects of national and local governments. Kepu, along with the Ministry of Health and the Chinese Medical Association, jointly organized a three-year 600 sessions of national grassroots reproductive tract infection prevention and control training to provide guidance for clinical medication for grassroots doctors. Starting from 2011, Kepu and the Medical and Health Technology Development Research Center of the Ministry of Health jointly established the China (HPV) database to provide theoretical basis for cervical cancer prevention and control, vaccine research and development, and the formulation of cervical cancer public relations and health policies. On the basis of significant achievements in the industrialization of molecular diagnosis, Kepu Group has established over 30 molecular medical laboratories in Hong Kong and key cities across the country. With the brand image of "Kepu Medical Laboratory, Nucleic Acid Diagnosis Expert", advanced molecular diagnosis technology is serving grassroots medical institutions across the country, expanding the company's business to the downstream industry chain, and achieving an integrated business model of "platform+reagent+service". Since the outbreak of the COVID-19 epidemic, relying on the profound experience in the field of nucleic acid molecular diagnosis in China, we have independently developed a series of respiratory pathogen detection products, formed a complete overall solution for COVID-19 detection, and protected people's life, health and safety with scientific and technological strength. Thirty two Kepu medical laboratories nationwide have become COVID-19 nucleic acid testing institutions designated by the Health Commission, actively responding to the call of the government, participating in large-scale COVID-19 nucleic acid testing and screening in Guangdong, Hubei, Beijing, Xinjiang, Liaoning, Hong Kong, Yunnan, Sichuan, Heilongjiang, Nanjing, Hunan, Chongqing, Henan, Shanghai, Fujian, Shaanxi, Guangxi and other places. In many national screening tasks, Kepu "Puji" air membrane laboratories have been invested and built The Kaipu "Triumph" shelter laboratory has improved the local nucleic acid detection ability, excellently completed the screening task, won the praise and affirmation of the local government, and accumulated a large number of rich COVID-19 screening experience in different application scenarios. As a national brand enterprise with a mission and responsibility, Kepu will continue to play a positive role in human health and work together with the biological industry to promote the development of medical and health care. |
| Headquarter | Chaozhou City |
| Establish Date | 6/13/2003 |
| Listed Code | 300639.SZ |
| Listed Date | 4/12/2017 |
| Chairman | Guan Qiao Zhong. |
| CEO | Wang Jianyu. |
| Website | www.hybribio.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
